A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

8600

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease
Cerebrovascular Accident
Coronary Heart Disease

Interventions

DRUG: Atorvastatin

Sponsor

Pfizer